合成与生物DMARDs疗效的系统文献综述:为2025年EULAR类风湿关节炎管理推荐更新提供证据
该系统文献综述检索2022年1月14日至2025年1月22日发表的随机对照试验,评估csDMARDs、bDMARDs、tsDMARDs及糖皮质激素治疗类风湿关节炎的疗效,共纳入72项研究,为2025年EULAR类风湿关节炎管理推荐更新提供证据。尽管新型药物的3期试验有限,但策略性研究和头对头研究为完善既定治疗算法提供了重要见解。
要点
- 72项研究纳入分析,涵盖csDMARDs、bDMARDs、tsDMARDs及糖皮质激素的疗效证据。
- 12种新化合物仅在2期RCT中评估,3期试验证据有限。
- 策略性试验比较传统治疗与bDMARD或tsDMARD策略,并探索精准医学方法。
核心结论
- 该系统文献综述与安全性综述共同为2025年EULAR类风湿关节炎管理推荐更新提供依据。
- 尽管新型药物的3期试验有限,策略性和头对头研究为完善既定治疗算法提供了重要见解。
研究设计与样本
- 检索Medline、Embase、Cochrane CENTRAL和Web of Science,纳入2022年1月14日至2025年1月22日发表的随机对照试验。
- 另检索数据库建库至2025年1月22日关于DMARDs、糖皮质激素和抗纤维化药物治疗RA相关间质性肺病及预防RA的研究。
- 共识别12567条参考文献,审阅390篇全文,最终纳入72项研究。
主要发现
- 3-4期RCT评估了csDMARDs(羟氯喹、艾拉莫德、来氟米特和甲氨蝶呤)、bDMARDs(阿巴西普、otilimab和ozoralizumab)及tsDMARDs(ivarmacitinib、peficitinib和托法替布)。
- 12种新化合物在2期RCT中评估,3篇文章探讨糖皮质激素。
- 策略性试验比较传统治疗与基于bDMARD或tsDMARD的策略,并探索滑膜活检指导治疗和治疗药物监测等精准医学方法。
- 另有证据涉及DMARD减量,2项RCT评估抗纤维化药物(尼达尼布和吡非尼酮)治疗RA相关间质性肺病,7项研究评估DMARDs在高危人群中预防RA。
临床怎么用
- 该系统文献综述为2025年EULAR类风湿关节炎管理推荐更新提供证据基础,支持对既定治疗算法进行进一步完善。
局限性
- 新型药物的3期随机对照试验有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This systematic literature review (SLR) updated evidence on the efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs) to inform the 2025 update of the European Alliance of Associations for Rheumatology (EULAR) management recommendations for rheumatoid arthritis (RA). METHODS: Medline (PubMed), Embase (OVID), Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomised controlled trials (RCTs) of conventional-synthetic, biological, and targeted-synthetic DMARDs (csDMARDs, bDMARDs, tsDMARDs), as well as GCs and biosimilars, published from 14 January 2022 to 22 January 2025. Additional searches on DMARDs, GCs, and antifibrotics for RA-associated interstitial lung disease (RA ILD), and on DMARDs and GCs for preventing RA in at-risk individuals, were conducted from database inception to 22 January 2025. RESULTS: A total of 12,567 references were identified; 390 full-texts were reviewed, and 72 studies were included. Phase 3-4 RCTs evaluated csDMARDs (hydroxychloroquine, iguratimod, leflunomide, and methotrexate), bDMARDs (abatacept, otilimab, and ozoralizumab), and tsDMARDs (ivarmacitinib, peficitinib, and tofacitinib). Twelve novel compounds were assessed in phase 2 RCTs, and 3 articles investigated GCs. Strategic trials compared conventional therapies with bDMARD- or tsDMARD-based strategies and explored precision-medicine approaches such as synovial biopsy-guided treatment and therapeutic drug monitoring. Additional evidence addressed DMARD tapering. Two RCTs assessed antifibrotics (nintedanib and pirfenidone) for RA ILD, and 7 studies evaluated DMARDs for RA prevention in at-risk populations. CONCLUSIONS: This SLR, together with the safety review, informed the 2025 update of the EULAR RA management recommendations. Although few phase 3 trials on novel agents were available, strategic and head-to-head studies provided important insights that enabled further refinement of the established treatment algorithm.
引用
- Konzett V, Laskou F, Smolen JS, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2026. PMID: 41997804. doi:10.1016/j.ard.2026.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。